Loading
Pharmanutra CS Stock: price and insider trades · Italy
Pharmanutra CS: what insiders have been doing
Only a handful of insider records exist for Pharmanutra CS, the last one from 26 May 2026, too few to describe a trend. Every figure here comes from the filings published by Consob and describes the past, not future prices; it is not investment advice.
Insider Decl.
4
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Analyst consensus: bullish or bearish?
Analysts rate Pharmanutra CS Strong Buy (bullish), based on 3 analysts. Average price target: €95.67.
Fundamental score
Ranked 6,377 of 24,148 companies
63.3
score / 100
Value42
Quality85
FCF yld2.4%
Earn yld2.9%
EV/EBITDA20.9x
ROE32%
Gross mgn77%
Net mgn15%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€72.60
Analyst consensus
3 analystsStrong buy
€92.00Target €95.67(+32%)€102.00
Income statement
Revenue€132.9M
Gross profit€102.9M77% margin
EBITDA€34.3M26% margin
Net income€20.0M14.4% margin
Valuation
PER (trailing)33.5x
PER (forward)23.2x
P/Book9.4x
Beta0.16
Balance sheet & cash
Market cap€695.2M
Total debt€20.5M
Free Cash Flow€16.4M
Debt / Equity26%
Profitability & ownership
ROE31.6%
ROA16.2%
% insiders65.0%
% institutions16.5%
Last declaration on 26 May 2026
About Pharmanutra CS
Pharmanutra CS is a company specialized in the health and pharmaceutical sector, providing innovative solutions for well-being. It is listed on the XMIL market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
